Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651546 | 0.92 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10228314 | 0.91 | POLB (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL6522346 | 0.91 | POLB (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10331118 | 0.91 | POLB (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL13576805 | 0.88 | POLB (0.54) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4579459 | 0.85 | LMNA (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4579454 | 0.85 | LMNA (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL19033324 | 0.84 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL16359951 | 0.84 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL22300660 | 0.84 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20160257954-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2016-09-08 | — | — | US | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-9376680-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | POLB 755/4885LMNA 2492/4885PDE3A 3083/4885 |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFH, SSB, RNASEH1 | POLB 702/4885LMNA 103/4885PDE3A 3203/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | POLB 1821/4885LMNA 303/4885PDE3A 3191/4885 |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, APOL1, LDLR | POLB 1285/4885LMNA 186/4885PDE3A 1963/4885 |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | MAPT, RNMT, NSUN2 | POLB 810/4885LMNA 1470/4885PDE3A 1925/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | POLB 144/4885LMNA 241/4885PDE3A 3619/4885 |
| US-20160257954-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SERPINC1, SERPINH1, SERPINE1 | POLB 583/4885LMNA 319/4885PDE3A 2099/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | POLB 770/4885LMNA 1116/4885PDE3A 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.